Polynovo Ltd (ASX: PNV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Polynovo Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.51 billion
P/E Ratio 856.00
Dividend Yield 0.00%
Shares Outstanding 690.23 million
Earnings per share 0.003
Dividend per share N/A
Year To Date Return 29.31%
Earnings Yield 0.12%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Polynovo Ltd (ASX: PNV)
    Latest News

    CSL share price Digitised bubbles of cells representing ASX biotech shares such as CSL
    Healthcare Shares

    Is the CSL share price the best ASX biotech buy right now?

    The CSL share price has been a strong performer for many years but is it the best ASX biotech share…

    Read more »

    man drawing upward curve on 2020 graph, asx share price growth
    Growth Shares

    Where I'd invest $10,000 in ASX shares for the future

    Why I'd like to invest $10,000 in Nextdc Limited (ASX: NXT) and 2 other ASX growth shares for a strong…

    Read more »

    New ASX share buy ideas
    ⏸️ Portfolio Construction

    3 tips for beginners investing in ASX shares

    Here are a few simple investing tips for beginners looking to build out their ASX share portfolio in the current…

    Read more »

    Growth Shares

    3 exciting ASX growth shares to buy with $3,000

    Here's why I would buy Pushpay Holdings Ltd (ASX:PPH) and these ASX growth shares with $3,000 right now...

    Read more »

    wooden blocks spelling deal with one block saying yes and no representing wesfarmers share price
    Growth Shares

    3 ASX shares I would buy right now at these prices

    Here's why I think PolyNovo and these 2 ASX shares are trading at attractive prices right now, given their strong…

    Read more »

    group of hands all giving thumbs up gesture
    Share Market News

    If you invested $50k in these ASX shares 3 years ago, you'd be a millionaire today

    If you invested $10k in each of these shares 3 years ago, you would be sitting on more than $1.3…

    Read more »

    coronavirus mask with a falling line graph on it
    Share Market News

    These ASX medical shares fell double figures in July – are they a buy?

    Investors in these two ASX medical shares have locked in recent gains sending prices down significantly. Are they worthy long-term…

    Read more »

    Growth Shares

    Why PolyNovo and these ASX healthcare shares could be long term market beaters

    PolyNovo Ltd (ASX:PNV) and these ASX healthcare shares could be long term markets beaters for Australian investors. Here's why...

    Read more »

    increasing bar graph created from medical tablets
    Healthcare Shares

    3 junior ASX healthcare shares with explosive growth potential

    For investors wishing to diversity into the healthcare sector, but who also want to look beyond big names like Cochlear…

    Read more »

    $100 notes multiplying into the future representing asx growth shares
    ⏸️ Investing

    Why Opthea shares could offer big growth potential

    Junior ASX healthcare company Opthea Ltd (ASX: OPT) has had a volatile year, but it could still be on the…

    Read more »

    Rocket launching into space
    Healthcare Shares

    Why the Polynovo share price could climb in August

    The Polynovo Ltd (ASX: PNV) has had a strong year but I think it could push even higher after its…

    Read more »

    Biotechnology graphics
    Share Market News

    4 exciting ASX biotech shares surging higher today

    The ASX biotech segment has been on fire today. Here we take a closer look at 4 ASX biotech shares…

    Read more »

    Frequently Asked Questions

    The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was listed on the ASX  on 26 November 1998 and is headquartered in Melbourne.

    No, the company does not historically pay dividends.

    PNV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Polynovo Ltd

    PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.

    NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.

    PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.

    PNV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $2.14 $0.04 1.90% 1,793,957 $2.12 $2.22 $2.11
    26 Mar 2024 $2.10 $-0.02 -0.94% 6,338,523 $2.10 $2.12 $2.06
    25 Mar 2024 $2.12 $-0.01 -0.47% 2,646,839 $2.15 $2.16 $2.09
    22 Mar 2024 $2.13 $-0.07 -3.18% 1,118,356 $2.18 $2.19 $2.10
    21 Mar 2024 $2.20 $0.06 2.80% 2,071,350 $2.19 $2.24 $2.17
    20 Mar 2024 $2.14 $-0.05 -2.28% 1,883,237 $2.21 $2.25 $2.12
    19 Mar 2024 $2.19 $-0.16 -6.81% 2,478,168 $2.37 $2.39 $2.17
    18 Mar 2024 $2.35 $0.02 0.86% 1,183,680 $2.31 $2.36 $2.30
    15 Mar 2024 $2.33 $0.01 0.43% 2,641,536 $2.30 $2.35 $2.22
    14 Mar 2024 $2.32 $-0.17 -6.83% 2,344,276 $2.51 $2.51 $2.30
    13 Mar 2024 $2.49 $0.01 0.40% 1,851,249 $2.49 $2.52 $2.46
    12 Mar 2024 $2.48 $0.08 3.33% 3,173,551 $2.42 $2.52 $2.41
    11 Mar 2024 $2.40 $0.01 0.42% 1,306,415 $2.39 $2.44 $2.37
    08 Mar 2024 $2.39 $0.10 4.37% 3,030,795 $2.30 $2.41 $2.27
    07 Mar 2024 $2.29 $0.04 1.78% 1,609,829 $2.29 $2.30 $2.27
    06 Mar 2024 $2.25 $0.01 0.45% 1,564,337 $2.23 $2.26 $2.17
    05 Mar 2024 $2.24 $0.03 1.36% 1,531,840 $2.22 $2.25 $2.16
    04 Mar 2024 $2.21 $0.01 0.45% 2,194,703 $2.27 $2.30 $2.14
    01 Mar 2024 $2.20 $-0.08 -3.51% 2,227,886 $2.25 $2.25 $2.16
    29 Feb 2024 $2.28 $0.15 7.04% 3,585,967 $2.10 $2.28 $2.08
    28 Feb 2024 $2.13 $0.15 7.56% 6,081,790 $2.02 $2.19 $2.01
    27 Feb 2024 $1.99 $-0.03 -1.49% 1,765,142 $2.01 $2.03 $1.94

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    31 Oct 2023 Robyn Elliott Buy 32,000 $38,080
    On-market trade.
    28 Jun 2023 Robyn Elliott Buy 27,000 $39,690
    On-market trade.
    08 Jun 2023 David Williams Buy 22,500 $36,000
    On-market trade.
    07 Jun 2023 David Williams Buy 14,453 $23,448
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David Williams Non-Executive DirectorNon-Executive Chairman Feb 2014
    Mr Williams was appointed as a Non-executive Director on 28 February 2014 and Chairman on 13 March 2014. Mr Williams is an experienced Director and investment banker with a track record in business development as well as in mergers and acquisitions and capital raising.
    Mr Bruce Rathie Non-Executive Director Feb 2010
    Mr Rathie was appointed a Director of PolyNovo on 18 February 2010. He is an experienced Company Director with a finance and legal background. He practised as a partner in a legal firm and acted as Senior Corporate Counsel to Bell Resources Limited.
    Dr Robyn Elliott Non-Executive Director Oct 2019
    Dr Elliott was appointed a Director of PolyNovo on 28 October 2019. Dr Elliott is currently Global Head, Strategic Portfolio Management at CSL Behring. Dr Elliott previously held Strategic Expansion and Quality Senior Director roles within CSL, was the Managing Director at IDT Australia and commenced her career at DBL Faulding.
    Mr Andrew Stuart Lumsden Non-Executive Director Jun 2021
    Mr Lumsden was appointed a Director of PolyNovo on 4 June 2021. He has more than 20 years' experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer.
    Mr Leon Hoare Non-Executive Director Jan 2016
    Mr Hoare was appointed a Director of PolyNovo on 27 January 2016. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew ANZ (all divisions) until 2015. He served as President of Smith & Nephew's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division.
    Ms Christine Emmanuel-Donnelly Non-Executive Director May 2020
    Ms Emmanuel-Donnelly was appointed a Director of PolyNovo on 13 May 2020. She has more than 30 years' local and international experience. She is Vice President of the Board of the Institute of Patent and Trade Mark Attorneys of Australia on Springboard Enterprises Life Sciences Council, is a non-executive director on the board of Medical Developments International and is a member of the Australian Institute of Company Directors.
    Mr Jan-Marcel Gielen Chief Financial OfficerCompany Secretary Dec 2018
    -
    Mr Swami Raote Chief Executive Officer Jul 2022
    -
    Swami Raote Chief Executive Officer
    -
    Jan-Marcel Gielen Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 94,468,202 13.69%
    J P Morgan Nominees Australia Pty Limited 58,519,477 8.48%
    Citicorp Nominees Pty Limited 26,811,635 3.88%
    Moggs Creek Pty Ltd (Moggs Creek Super A/C) 19,010,112 2.75%
    BNP Paribas Noms Pty Ltd (Drp) 12,383,050 1.79%
    Lateral Innovations Pty Ltd (Trust A/C) 10,924,103 1.58%
    National Nominees Limited 8,413,960 1.22%
    Mr Anthony Shane Kittel + Mrs Michele Therese Kittel (Kittel Family Super A/C) 8,055,789 1.17%
    BNP Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) 5,909,896 0.86%
    Sandhurst Trustees Ltd (Endeavor Asset Mgmt Mda A/C) 5,739,049 0.83%
    Netwealth Investments Limited (Wrap Services A/C) 4,276,587 0.62%
    Ms Simone Maree Beks 4,185,095 0.61%
    Mr Paul Gerard Brennan 4,185,095 0.61%
    Commonwealth Scientific And Industrial Research Organisation 4,081,250 0.59%
    Mr Matthew James Avery 3,631,338 0.53%
    Mrs Li-Hsien Tsai 3,292,698 0.48%
    Mr David Kenley 3,139,855 0.45%
    Dr Marcus James Dermot Wagstaff + Mrs Lara Kate Wagstaff 3,072,166 0.45%
    Mr Laurent Fossaert 2,929,961 0.42%
    MR CHRIS DAWBORN (HASKALI SUPER FUND A/C) 2,870,271 0.42%

    Profile

    since

    Note